Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United StatesIPO:
25 June 2015Website:
http://www.glaukos.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
after hours | Tue, 05 Nov 2024 00:58:44 GMTDividend
Analysts recommendations
Institutional Ownership
GKOS Latest News
Call Start: 16:30 January 1, 0000 5:31 PM ET Glaukos Corporation. (NYSE:GKOS ) Q3 2024 Earnings Conference Call November 04, 2024, 04:30 PM ET Company Participants Chris Lewis - VP, IR and Corporate Affairs Tom Burns - Chairman and CEO Joe Gilliam - President and COO Alex Thurman - CFO Conference Call Participants Tom Stephan - Stifel Lawrence Biegelsen - Wells Fargo Ryan Zimmerman - BTIG Matthew O'Brien - Piper Sandler Allen Gong - JPMorgan David Saxon - Needham Michael Sarcone - Jefferies Joanne Wuensch - Citigroup Steve Lichtman - Oppenheimer Anthony Petrone - Mizuho Operator Welcome to Glaukos Corporation's Third Quarter 2024 Financial Results Conference Call.
Glaukos (GKOS) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.50 per share a year ago.
Glaukos (GKOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Glaukos announces positive second Phase 3 confirmatory pivotal trial for Epioxa.
GKOS stock is being driven by strong product demand, international expansion and pipeline progress, which position it for long-term growth despite supply risks.
GKOS continues to benefit from a robust product portfolio and a strong pipeline. However, stiff competition remains a woe.
GKOS continues to benefit from a robust demand for its products as well as expansion in new markets. A strong development pipeline raises optimism.
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
While the top- and bottom-line numbers for Glaukos (GKOS) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Glaukos' (GKOS) second-quarter 2024 results showcase growth in revenues on the back of strong adoption of its glaucoma products like iStent and iDose TR. Loss at the operating level raises concern.
What type of business is Glaukos?
Glaukos Corporation is a company specializing in ophthalmic medical technologies and pharmaceuticals, focusing on developing new methods for treating glaucoma, corneal diseases, and retinal diseases. The corporation was founded in 1998, with its headquarters in San Clemente, California. The company has developed micro-invasive glaucoma surgery (MIGS) as an alternative to traditional glaucoma treatment, and in 2012 launched its first MIGS device for sale. They have also developed a patented bioactivated pharmaceutical therapy for treating corneal disorders. Glaukos Corporation is involved in developing lines of surgical devices, pharmaceutical therapy, and implantable biosensors for treating the progression of glaucoma, corneal diseases such as keratoconus, dry eye, and a variety of other conditions.
What sector is Glaukos in?
Glaukos is in the Healthcare sector
What industry is Glaukos in?
Glaukos is in the Medical Devices industry
What country is Glaukos from?
Glaukos is headquartered in United States
When did Glaukos go public?
Glaukos initial public offering (IPO) was on 25 June 2015
What is Glaukos website?
https://www.glaukos.com
Is Glaukos in the S&P 500?
No, Glaukos is not included in the S&P 500 index
Is Glaukos in the NASDAQ 100?
No, Glaukos is not included in the NASDAQ 100 index
Is Glaukos in the Dow Jones?
No, Glaukos is not included in the Dow Jones index
When was Glaukos the previous earnings report?
No data
When does Glaukos earnings report?
Next earnings report date is not announced yet